Vertex Pharmaceuticals Inc.

Mr. Emmens is Chairman and CEO of Vertex. He has over 33 years of experience in the pharmaceutical industry, including Shire Pharmaceuticals Group plc and businesses operated by Merck KGaA and Merck & Co. He became our Chairman, CEO and President in 2009 and has been a member of our Board of Directors since 2004. Mr. Emmens is the Chairman of the Board of Directors of Shire and was its Chief Executive Officer from March 2003 through June 2008. Before joining Shire in 2003, Mr. Emmens served as president of Merck KGaA’s global prescription pharmaceuticals business in Darmstadt, Germany. In 1999, he joined Merck KGaA and established EMD Pharmaceuticals, its United States prescription pharmaceutical business. Mr. Emmens held the position of President and Chief Executive Officer at EMD Pharmaceuticals from 1999 to 2001. Earlier, Mr. Emmens held various positions, including Chief Executive Officer, at Astra Merck, Inc. as well as several positions at Merck & Co., Inc. Mr. Emmens received a B.S. degree in business management from Fairleigh Dickinson University.

Ian Smith joined Vertex in November 2001. Prior to joining Vertex, Mr. Smith served as a partner in the Life Science and Technology Practice Group of Ernst & Young LLP, an accounting firm, from 1999 to 2001. As Vertex’s CFO, Mr. Smith holds responsibility for a wide variety of core functions at Vertex, including Finance, Strategic Communications, Information Systems and Operations. Mr. Smith is also a member of the Executive Team at Vertex. Mr. Smith received a B.A. with honors in Accounting and Finance from Manchester Metropolitan University. Mr. Smith is a current member of the American Institute of Certified Public Accountants, the Institute of Chartered Accountants of England and Wales, and the Financial Executives Institute. Mr. Smith is a member of the Board of Directors of Acorda Therapeutics, Inc, Epix Pharmaceuticals, Inc. and TolerRx Inc. Additionally, he is a board member of the Massachusetts Biotechnology Council and is Chair of its Policy Committee.

Joshua S. Boger , Ph.D., has served as a member of our board of directors since December 2005. He was a founder of Vertex Pharmaceuticals, Inc., a biotechnology company, and has served as Vertex's Chief Executive Officer since January 2000 and also as its President since February 2006. He also served as Chairman of Vertex's board of directors from January 2000 to May 2006. Dr. Boger received his B.A. in chemistry and philosophy from Wesleyan University and his M.S. and Ph.D. degrees in chemistry from Harvard University.

Majda Benhayoun, Ph.D. is currently Director of Program and Portfolio Management at Vertex Pharmaceuticals and has been working in drug development for the past 3 years. Prior to joining Vertex, Majda worked in Clinical Project Management for more than 15 years, with her first 11 years at Aventis Pharma, previously Rhone-Poulenc Rorer, and then 4 years at PAREXEL International where she held a position of Clinical Project Director. Majda has extensive experience in project management both strategic and operational in early and late stages of drug development in various therapeutic areas, some of them being CNS, inflammation, or immunology. As Clinical Program Manager, Majda has a broad experience in the concepts of clinical trials including planning and execution of clinical trials from single site Phase I to large and complex multinational Phase III trials concluding in NDA/MAA filing.

Array